Literature DB >> 21469128

Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.

Jin-Sung Chung1, Ponciano D Cruz, Kiyoshi Ariizumi.   

Abstract

Most coinhibitory receptors regulate T-cell responses through an ITIM that recruits protein tyrosine phosphatases (PTPs) to mediate inhibitory function. Because syndecan-4 (SD-4), the coinhibitor for DC-associated heparan sulfate proteoglycan integrin ligand (DC-HIL), lacks such an ITIM, we posited that SD-4 links with a PTP in an ITIM-independent manner. We show that SD-4 associates constitutively with the intracellular protein syntenin but not with the receptor-like PTP CD148 on human CD4(+) T cells. Binding to DC-HIL allowed SD-4 to assemble with CD148 through the help of syntenin as a bridge, and this process upregulated the PTP activity of CD148, which is required for SD-4 to mediate DC-HIL's inhibitory function. Using a mouse model, we found SD-4 to be located away from the immunological synapse formed between T cells and APCs during activation of T cells. These findings indicate that SD-4 is unique among known T-cell coinhibitors, in employing CD148 to inhibit T-cell activation at a site distal from the synapse.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469128      PMCID: PMC3128389          DOI: 10.1002/eji.201041233

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability.

Authors:  Tsvetelina Pentcheva-Hoang; Lieping Chen; Drew M Pardoll; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-29       Impact factor: 11.205

2.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

3.  Negative regulation of human T cell activation by the receptor-type protein tyrosine phosphatase CD148.

Authors:  S G Tangye; J Wu; G Aversa; J E de Vries; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

4.  Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation.

Authors:  J E Baker; R Majeti; S G Tangye; A Weiss
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

5.  Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.

Authors:  Hideo Akiyoshi; Jin-Sung Chung; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2010-02-22       Impact factor: 5.422

6.  The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).

Authors:  Leslie J Holsinger; Kevin Ward; Bill Duffield; Joseph Zachwieja; Bahija Jallal
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

7.  A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.

Authors:  Takamune Takahashi; Keiko Takahashi; Raymond L Mernaugh; Nobuo Tsuboi; Hua Liu; Thomas O Daniel
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

8.  The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Authors:  Jin-Sung Chung; Makoto Bonkobara; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

9.  Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells.

Authors:  Takayoshi Owada; Norihiko Watanabe; Mie Oki; Yoshihiro Oya; Yasushi Saito; Takashi Saito; Itsuo Iwamoto; Theresa L Murphy; Kenneth M Murphy; Hiroshi Nakajima
Journal:  J Leukoc Biol       Date:  2009-11-05       Impact factor: 4.962

10.  Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.

Authors:  Jin-Sung Chung; Irene Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

View more
  12 in total

1.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

2.  Generation and functional characterization of MDSC-like cells.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Jonas Schulte-Schrepping; Julia Friederike Andrea Wolff; Kathrin Klee; Thomas Ulas; Niklas Arndt Schmacke; Solveig Nora Daecke; Kati Riethausen; Joachim L Schultze; Peter Brossart
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

Review 3.  GPNMB: a potent inducer of immunosuppression in cancer.

Authors:  Anna-Maria Lazaratos; Matthew G Annis; Peter M Siegel
Journal:  Oncogene       Date:  2022-09-01       Impact factor: 8.756

4.  Syndecan-2 can promote clearance of T-cell receptor/CD3 from the cell surface.

Authors:  Xavier Rovira-Clavé; Maria Angulo-Ibáñez; Oriol Noguer; Enric Espel; Manuel Reina
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

5.  The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.

Authors:  Jin-Sung Chung; Kyoichi Tamura; Hideo Akiyoshi; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2014-02-10       Impact factor: 5.422

6.  The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.

Authors:  Jin-Sung Chung; Mizuki Tomihari; Kyoichi Tamura; Tetsuhito Kojima; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

7.  The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.

Authors:  Michael Gutknecht; Julian Geiger; Simone Joas; Daniela Dörfel; Helmut R Salih; Martin R Müller; Frank Grünebach; Susanne M Rittig
Journal:  Cell Commun Signal       Date:  2015-03-24       Impact factor: 5.712

Review 8.  Heparan Sulfate Proteoglycans May Promote or Inhibit Cancer Progression by Interacting with Integrins and Affecting Cell Migration.

Authors:  Mariana A Soares; Felipe C O B Teixeira; Miguel Fontes; Ana Lúcia Arêas; Marcelo G Leal; Mauro S G Pavão; Mariana P Stelling
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

9.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

10.  DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.

Authors:  Jin-Sung Chung; Kyoichi Tamura; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Invest Dermatol       Date:  2014-06-17       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.